Report copyright - Gary Phillips CEO April 2019 · Partnering process –H1 2019 2. Boehringer Ingelheim acquired SSAO inhibitor (BI 1467335) to report clinical proof of concept in two major diseases
Please pass captcha verification before submit form
Please pass captcha verification before submit form